Eiko Lifesciences Ltd
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
- Market Cap ₹ 74.6 Cr.
- Current Price ₹ 54.4
- High / Low ₹ 74.9 / 42.0
- Stock P/E 23.1
- Book Value ₹ 42.8
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Promoter holding is low: 37.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 2.36 | 4.27 | 10.40 | 37.66 | 41.14 | |
| 1.98 | 4.95 | 14.91 | 34.89 | 35.90 | |
| Operating Profit | 0.38 | -0.68 | -4.51 | 2.77 | 5.24 |
| OPM % | 16.10% | -15.93% | -43.37% | 7.36% | 12.74% |
| 0.04 | 0.04 | 0.01 | 1.20 | 1.23 | |
| Interest | 0.09 | 0.19 | 0.24 | 0.17 | 0.25 |
| Depreciation | 0.08 | 0.17 | 0.19 | 0.74 | 0.92 |
| Profit before tax | 0.25 | -1.00 | -4.93 | 3.06 | 5.30 |
| Tax % | 20.00% | -21.00% | -26.77% | 24.51% | |
| 0.20 | -0.78 | -3.62 | 2.32 | 4.07 | |
| EPS in Rs | 0.31 | -0.69 | -2.98 | 1.86 | 2.62 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 12% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 3.82 | 3.82 | 3.82 | 13.76 | 13.72 |
| Reserves | 1.74 | 1.10 | -0.87 | 43.03 | 45.06 |
| 1.74 | 1.37 | 1.61 | 2.76 | 1.01 | |
| 3.66 | 3.01 | 7.49 | 6.56 | 4.97 | |
| Total Liabilities | 10.96 | 9.30 | 12.05 | 66.11 | 64.76 |
| 1.68 | 1.71 | 1.75 | 23.12 | 22.61 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 3.17 | 1.72 | 0.10 | 7.15 | 7.21 |
| 6.11 | 5.87 | 10.20 | 35.84 | 34.94 | |
| Total Assets | 10.96 | 9.30 | 12.05 | 66.11 | 64.76 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | |
|---|---|---|---|---|
| 0.00 | 0.16 | -0.33 | 2.92 | |
| 0.00 | -0.30 | -0.71 | -11.44 | |
| 0.00 | -0.55 | 0.95 | 6.96 | |
| Net Cash Flow | 0.00 | -0.69 | -0.09 | -1.57 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 225.81 | 73.51 | 41.41 | 104.58 |
| Inventory Days | 819.93 | 287.76 | 153.96 | 64.48 |
| Days Payable | 605.69 | 174.40 | 184.66 | 36.99 |
| Cash Conversion Cycle | 440.04 | 186.87 | 10.72 | 132.07 |
| Working Capital Days | 80.42 | -1.71 | -151.62 | 143.73 |
| ROCE % | -11.83% | -105.39% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23h - Newspaper Advertisement for 01st Extra-Ordinary General Meeting of the Company for the Financial Year -25-26 to be held on Wednesday, 07th January, 2026
-
01St Extra-Ordinary General Meeting To Be Held On Wednesday, 07Th January, 2026
1d - EGM 07-Jan-2026 to approve 33,00,000 warrants (₹18.15Cr) and 6,75,000 shares (₹3.71Cr) for SSM acquisition funding.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Definitive agreement to acquire 51% of SSM Formulations; WHO-GMP facility, capacity 300 crore tablets.
-
Announcement under Regulation 30 (LODR)-Issue of Securities
11 Dec - Approved 51% acquisition of SSM Formulations for ₹18.00 crore; preferential raises ₹18.15cr (warrants) and ₹3.71cr (shares); EGM 07-Jan-2026.
-
Announcement under Regulation 30 (LODR)-Acquisition
11 Dec - Approved 51% acquisition for Rs18.00 crore; warrants Rs18.15 crore; equity Rs3.71 crore; EGM Jan 7, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.